← FDA DRUG APPROVALS

FDA ANDA · ANDA202116

OXYCODONE HYDROCHLORIDE

Sponsor: ALVOGEN

APPLICATION
ANDA202116
TYPE
ANDA
ORIGINAL APPROVAL
2011-12-30
LATEST ACTION
2026-06-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

OXYCODONE HYDROCHLORIDEPrescription
OXYCODONE HYDROCHLORIDE 15MG · TABLET · ORAL
OXYCODONE HYDROCHLORIDEPrescription
OXYCODONE HYDROCHLORIDE 30MG · TABLET · ORAL
OXYCODONE HYDROCHLORIDEPrescription
OXYCODONE HYDROCHLORIDE 5MG · TABLET · ORAL

Approval history

2026-06-18REMS · Supplement 15AP
2025-01-23Labeling · Supplement 13 · standardAP
2025-01-23Labeling · Supplement 8 · standardAP
2025-01-23Labeling · Supplement 6 · standardAP
2025-01-23Labeling · Supplement 4 · standardAP
2025-01-23Labeling · Supplement 12 · standardAP
2025-01-23Labeling · Supplement 10 · standardAP
2024-10-31REMS · Supplement 11AP
2018-09-18REMS · Supplement 5AP
2011-12-30Not Applicable · OriginalREMSAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →